D&D Pharmatech Inc. (KOSDAQ:347850)

South Korea flag South Korea · Delayed Price · Currency is KRW
199,500
-1,000 (-0.50%)
Oct 10, 2025, 3:30 PM KST
-0.50%
Market Cap2.17T
Revenue (ttm)9.33B
Net Income (ttm)-37.11B
Shares Out10.86M
EPS (ttm)-3,495.95
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume285,564
Average Volume880,950
Open202,500
Previous Close200,500
Day's Range194,900 - 202,500
52-Week Range32,350 - 239,500
Betan/a
RSI63.45
Earnings DateNov 14, 2025

About D&D Pharmatech

D&D Pharmatech Inc., a clinical-stage biotech company, develops medicines in South Korea and the United States. It develops NLY01-PD, NLY01-AD, and NLY01-D that are in Phase II clinical trials for the treatment of Parkinson’s disease (PD), Alzheimer’s disease (AD), and type 2 diabetes; and P4M01, which has completed Phase IIa clinical trials to treat periodontal disease. The company also develops DD01 that is in Phase I clinical trials for the treatment of obesity/diabetes/nonalcoholic steatohepatitis (NASH); TLY012, which is Phase I clinical t... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 347850
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.